Novocure Ltd (NVCR) is up more than +11% after the US FDA approved the company’s Optune Lua to treat metastatic non-small cell lung cancer in adults who have progressed on or after a platinum-based ...
Pre-Market U.S. Stock Movers Novocure (NVCR) soared about +30% in pre-market trading after the U.S. FDA approved its portable lung cancer treatment, Optune Lua. J.B. Hunt Transport Services (JBHT) ...
ASML extends losses after cutting sales guidance, Nvidia stock edges higher, and third-quarter earnings at Morgan Stanley top ...
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
Retired tennis star Serena Williams said she underwent a procedure to remove a benign branchial cyst "the size of a small ...
The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.
US stock futures traded in a stable manner Wednesday, steadying after the previous season’s tech-inspired losses as quarterly ...
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...
The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...
Novocure shares are surging 35% after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung cancer. Interactive Brokers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback